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Purpose: The purpose of the study was to develop and evaluate different lipid-based 
  formulations for parenteral administration, as potential novel carrier systems for lipophilic 
drugs, and to turn an unstable drug such as chlorambucil into a useful one.
Methods: A two-stage, high-pressure homogenizer was used to yield a very fine monodispersed 
lipid nanosphere. The strategy of combining egg yolk phospholipid and nonionic emulsifier 
(Lutrol F 68 and Tween 80) as an emulsifier mixture was adopted to increase safety and tol-
erance. The final lipid nanospheres, in a lipophilic mixture consisting of three components, 
monostearin, medium-chain triglycerides and soya oil, were evaluated for physicochemical 
properties, such as particle size, surface morphology, drug-entrapment efficiency, drug-loading 
capacity, lyophilization and in vivo drug-release behavior.
Results: A monodispersed lipid nanosphere with a mean particle size ranging from 90 to 150 nm 
was achieved. The optimized injectable cryoprotectants for lipid nanosphere were sucrose (7.5%) 
and mannitol (7.5%), which can stabilize the particle size (LD50) at approximately 129 nm 
after reconstitution. The results show that the formulation can effectively administer anticancer 
drugs and thus improve patient quality of life.
Conclusions: The novel lipid nanosphere complex developed is a useful anticancer drug 
delivery vehicle for parenteral administration. The formulation strategy has the potential for the 
development of further methods of drug delivery for a wide variety of anticancer drugs.
Keywords: lipid nanosphere, parenteral application, pharmacokinetics, nanotechnology, 
chlorambucil
Introduction
Inhibition of tumor-associated angiogenesis has become one of the most promising 
developments in cancer treatment, which has resulted in the evaluation of a large 
number of angiogenesis inhibitors in clinical trials.1 Chlorambucil (CHL), a nitrogen 
mustard, is the primary treatment for patients with chronic lymphocytic leukemia (CLL) 
and is used in the pharmacotherapy of lymphomas, and advanced ovarian and breast 
carcinomas.2 It contains a nitrogen mustard group that transfers alkyl groups to amino, 
carboxyl, sulfhydryl and phosphate moieties (Figure 1).3 In the early development 
programs, it became apparent that nitrogen mustards were the most effective antitumor 
agents, probably through their ability to form interstrand cross-links in DNA, and also 
to form adducts with RNA and protein. It was also shown that alkylating cytostatic 
drugs influence the regulation of angiogenesis, already in nontoxic concentrations,4 International Journal of Nanomedicine 2010:5
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Figure 1 chemical structure of chlorambucil.
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and lead to a reduction in endothelial precursors in blood 
after chemotherapy.5 In this study, CHL was chosen as a 
model drug, because of the need to find new formulations to 
administer the drug more effectively and thus provide a useful 
lipid-based formulation for parenteral administration.
Over the last two decades, emulsions,6 liposomes,7 solid 
lipid nanoparticles (SLN), nanostructured lipid carriers,8–11 
and lipid nanospheres (LNS)12 have been developed and 
used as parenteral drug delivery carriers. These various lipid 
  carriers can enhance the efficacy and reduce the   to  xicity 
of antitumor drugs,13 and lipid carriers are receiving an 
increasing amount of attention as drug delivery systems 
for cancer chemotherapy. However, the development of 
intravenous lipid carriers is a very challenging task, and prob-
lems such as drug entrapment, crystallization,   solubility and 
chemical degradation are still difficult to overcome, especially 
degradation of unstable antitumor drugs caused by high-
temperature sterilization or hydrolysis. In this study, a novel 
injectable LNS formulation system was developed based 
on three main production principles, to solve many of the 
production issues involved in turning an unstable anticancer 
agent into an effective drug. First, the particle diameter and 
cumulative distribution were maintained at less than 200 nm 
to meet the filtration sterilization requirements. This diameter 
is essential for anticancer drugs because most anticancer 
drugs are susceptible to heating-induced decomposition. 
Second, a biocompatible surfactant mixture (Lutrol F 68 and 
Tween 80) was used for intravenous injection. The use of 
this combination may have the beneficial effect of reducing 
drug formulation toxicity by decreasing the content of each 
surfactant. Third, high-quality, freeze-dried characteristics of 
the anticancer drug-loaded LNS were obtained by replacing 
some of the liquid oils with the safest solid lipid, monostearin, 
in the formulation. We determined whether the use of LNS-
containing complex oils and a mixture of emulsifiers could 
efficiently deliver anticancer drugs for intravenous admin-
istration. This study aimed to evaluate different lipid-based 
nanospheres that were formulated by combining medium-
chain triglycerides/long-chain triglycerides (MCT/LCT) 
and monostearin as a lipophilic mixture, and using egg yolk 
phospholipid and nonionic emulsifiers (Lutrol F 68 and 
Tween 80) as an emulsifier mixture. It was expected that this 
novel delivery carrier would give a smaller particle size and a 
much safer formulation strategy for parenteral administration 
than   currently available delivery systems.
Materials and methods
Materials
Egg lecithin 80 was purchased from Lipoid Corp. (Lipoid K G, 
Germany). Poloxamer 188 (Lutrol F 68) was supplied by 
BASF (Ludwigshafen, Germany). Tween 80 for parenteral use 
was purchased from Shenyu Medicine and Chemical Industry 
Corp. (Shanghai, China). Soybean oil (LCT) for parenteral use 
was a gift from Beiya Corp. (Tieling, China). Miglyol® 812 
(caprylic/capric triglycerides, MCT) was obtained from Huls 
(Witten/Ruhr, Germany). Monostearin was purchased from 
Shanghai Chemical Reagent Corp. (Shanghai, China). PEG-
40 was purchased from Sigma (St. Louis, MO). Chlorambucil 
(purity 98.8%) was purchased from Beijing Lunarsun Phar-
maceutical Corp. (Beijing, China).
Solubility study of chlorambucil
The solubility of drugs in the lipophilic mixture (soybean 
oil and MCT) was determined. Samples were prepared by 
adding an excess amount of drugs to 1 mL of lipophilic 
mixture and shaking reciprocally on a shaking water bath at 
37 ± 0.5°C for 24 hours. After centrifugation at 12,000 rpm 
for 20 minutes, the supernatant was diluted with ethanol and 
assayed by reversed phase high-performance liquid chroma-
tography (RP-HPLC).
Drugs were analyzed according to the method of Ganta 
et al14 with modification. The HPLC system consisted of a 
200 mm × 4.6 mm RP 18 BonChrom column packed with 
5-µm particles (Agela Tech, Newark, DE), a Shimadzu LC-
10AT pump and a Shimadzu SPD-10A ultraviolet detector 
  (Shimadzu, Kyoto, Japan). The mobile phase consisted of 
methanol and a 0.2% (v/v) acetic acid solution (80:20, v/v), 
the injection volume was 20 µL, the detection was set at 
258 nm at a flow rate of 1.0 mL⋅min−1, and the column was 
set at 30°C.
Formulation and preparation  
of lipid nanospheres
High-pressure homogenization, which is a reliable and 
  powerful technique for industrial scale-up, was used 
to prepare fine LNS. The lipophilic mixture differed in 
  composition, with monostearin and various amounts of 
soybean oil or MCT or binary liquid–oil mixtures (Table 1) International Journal of Nanomedicine 2010:5
Table 1 Formulation components of the lipophilic mixture of the 
final lipid nanospheres
Lipophilic mixture Monostearin 
(mg⋅mL-1) 
LCT 
(mg⋅mL-1)
MCT 
(mg⋅mL-1)
Lipophilic mixture 1 40 20 –
Lipophilic mixture 2 40 10 10
Lipophilic mixture 3 40 – 20
Abbreviations: LcT, long-chain triglycerides; McT, medium-chain triglycerides.
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while maintaining a constant final concentration of lipid. 
The mixture was heated at 55°C. Then, drugs (0.7 mg) 
were added to the lipophilic mixtures and dispersed by 
magnetic stirring. The aqueous phase was prepared by 
dissolving a mixture of emulsifiers with different ratios 
of Lutrol F 68, Tween 80 and E80 (Table 2) in distilled 
water under magnetic stirring. Aqueous phases were heated 
separately to 60°C, and then the hot water and surfactants 
were poured into the hot lipid phase and mixed using a 
magnetic stirrer. Next, 30 mL of the coarse dispersion was 
passed through a high-pressure homogenizer with a two-
stage homogenizing valve assembly (ATS, AH100D) at a 
pressure of 700 bars for 10 cycles, and, finally, the LNS 
were obtained (pH ∼7.0).
The following formulations were optimized as a whole, 
with different ratios of lipophilic mixtures and surfactant 
mixtures. The formulation and production process was 
optimized according to Bock et al.15
Drug entrapment efficiency 
determination and loading capacity
The total LNS drug content (Winitial drug) and free-drug content 
(Wfree drug) in the final suspension were determined by HPLC 
for encapsulation.
Free drugs were separated using an ultrafiltration 
method. The LNS were diluted with 0.2% (v/v) acetic acid 
approximately 10 times, instead of the mobile phase, to 
avoid dissolving LNS. Based on a previous report,16 the 
diluted sample was placed in the outer chamber and then 
ultrafiltrated at 4000 rpm for 10 min using an Amicon 
Ultra 10K device (MW 10000 Amicon Ultra centrifugal filter 
devices with   low-binding Ultracel@ membranes); the ultra-
filtrate was assayed by HPLC after diluting with the mobile 
phase, and then the free drug content was determined.
A total of 1 mL of LNS was dissolved in 25 mL of 
methanol under a water bath at 50°C for 2 minutes. Then, the 
sample was diluted 20 times with the mobile phase, 20 µL 
were subsequently injected into HPLC for analysis, and, 
finally, the total drug content in the LNS suspension was 
calculated. All sample analyses were performed within 
12 hours. Entrapment efficiency (EE%) was determined by 
the following equation:
 
EE% =
W- W
W
100%
initial drug free drug
initial drug  
Addition acetic acid was added to lipophilic mixtures, 
adjusting the pH to 3.0 against drug hydrolysis during the 
preparation process of the optimized LNS formulation. After 
adding acetic acid to the oil phase, a high CHL entrapment 
efficiency (.99.0%) was achieved.
LNS with a moderate loading capacity of 0.7 mg⋅mL−1 
were produced and could be dissolved in liquid–lipophilic 
mixtures (MCT and LCT) according to solubility studies. 
The other materials played a significant role in the drug 
solubilization in LNS, including the presence of phos-
pholipids and surfactants. It was possible to incorporate 
higher concentrations of drugs into the LNS than the 
original drug load according to solubility studies, and LNS 
with CHL concentrations of 1.0 and 1.5 mg⋅mL−1 were   
produced.
Particle size distribution
Laser diffraction (LD) was used to determine the volume 
average diameter (Nicomp PSS ZW 380, Santa Barbara, 
CA) for the fresh and reconstituted lipid nanospheres. Prior 
to measurement, lyophilized LNS were reconstituted with fil-
tered water. In this work, D (v,10), D (v,50) and D (v,90) were 
used, representing diameters at 10%, 50%, and 90% cumu-
lative volume, respectively, and D (v,50) is the median   
diameter.
Transmission electron microscopy (TeM)
A TEM instrument (TEM-1200EX; JEOL, Tokyo Japan) 
was used to examine the morphology of the optimized LNS. 
A drop of drug-loaded LNS was placed on the copper grids 
to form a film, followed by negative staining with a drop of 
2% (w/v) phosphotungstic acid. The air-dried sample was 
then viewed by TEM.
Table 2 Formulation components of the surfactant mixture of 
the final lipid nanospheres
Surfactant 
mixture
E80 
(mg⋅mL-1) 
Lutrol F 68 
(mg⋅mL-1)
Tween 80 
(mg⋅mL-1)
Surfactant 1 20 10 30
Surfactant 2 20 20 20
Surfactant 3 20 30 10International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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Differential scanning calorimetry (DSc)
DSC was performed to determine the phase transition of 
optimized LNS complex. About 25 mg of sample were 
weighed into standard aluminium pans using an empty pan 
as reference. The samples were heated from 0 to 90°C at a 
rate of 10°C⋅min−1 (DSC-60; Shimadzu Corp.).
Freeze-drying of lipid nanospheres
As acetic acid was used to prevent drug hydrolysis during 
formulation preparation, the optimized LNS were read-
justed to neutral pH with 0.1 M sodium hydroxide before 
lyophilization. To optimize the cryoprotectants for the LNS 
dispersion during the freeze-drying process, mannite, lactose, 
glucose, sorbitol, trehalose and mannose were chosen for intra-
venous application. Various amounts of cryoprotectants were 
added to the LNS dispersions, each sample was pre-cooled at 
−70°C in a deep-freeze for 4 hours, and then freeze-drying 
was carried out in a refrigerator (Eyela FDU-110; Tokyo, 
Rikakikai Co, Ltd). Primary drying was performed at a shelf 
temperature of −40°C for 14 hours,   followed by a secondary 
drying step at a shelf temperature of 10°C for 2 hours; finally, 
the powdered LNS were obtained. The lyophilized products 
were reconstituted in distilled water by manual shaking and 
then sonication for 1 minute using an ultrasonic water-bath 
sonicator (KQ-100DB; Kunshan Co. Ltd., China).
In vivo studies
The experiments were carried out using Kunming female 
mice (28–32 g). Two groups of 36 mice were used to evaluate 
the pharmacokinetics of CHL-LNS, and, for comparison, 
CHL injections were prepared based on a reported method.17 
The mice were purchased from Shenyang Pharmaceutical 
University’s animal center. Three mice were used at each time 
point. After the intravenous administration of 10 mg⋅kg−1 of 
drug, blood samples were obtained from the retro-orbital 
sinus at 5, 15, 30, 45, 60 and 90 minutes. The blood was 
instantly centrifuged at 6000 rpm for 5 minutes. Blood sample 
treatment was performed by adding 0.3 mL (2 µg⋅mL−1 
internal standard) of methanol-acetonitrile (50:50, v/v) to 
0.1 mL of plasma. A tissue distribution study was carried out 
at the same time for 15, 45, 60, and 90 minutes, respectively. 
Tissues (heart, liver, spleen, lung, and kidney) were cut and 
rinsed with cold saline with 0.2% (v/v) acetic acid. Then, they 
were homogenized with 4 volumes of methanol-acetonitrile 
(50:50, v/v) with a 2 µg⋅mL−1 internal standard. Protein 
precipitation of all plasma and tissue samples was carried 
out after vortexing for 5 minutes. The samples were kept 
on ice for 30 minutes and then centrifuged at 6000 rpm for 
5 minutes to precipitate the proteins; all samples were main-
tained at −20°C until 20 µL of the supernatant was injected 
into the HPLC for analysis.
The separation was carried out with the mobile phase 
consisting of 0.03 M KH2PO4:MEOH = 30:70 (v/v, pH 3.0, 
adjusted with 0.5 M H3PO4) at a flow rate of 1.0 mL⋅min−1. 
Chromatograms were monitored at 258 nm, and the tempera-
ture of the column was kept at 30°C. The selected internal 
standard is (2-chloro-N-[[(2-chlorophenyl)amino]carbonyl]-
2-chloro-N-(2-chlorophenylcarbamoyl)acetamide).
The study was approved by the University Animal Ethics 
Committee and complied with the Animal Ethics Committee 
Guidelines.
Results and discussion
Solubility study
The solubilities of CHL in soybean oil and MCT were 36.4 
and 78.2 mg⋅mL−1 at 37°C, respectively. LCT, MCT or a 
combination of both was used as the lipophilic mixture for 
the preparation of the LNS, as it is important to incorporate 
the drug into the inner phase of the LNS.
Because of the solid state of monostearin, it was very 
  difficult to determine the real solubility of CHL under normal 
temperatures; therefore, the whole-drug loading capacities 
in LNS with increasing drug concentrations of 0.7, 1.0, and 
1.5 mg⋅mL−1 were determined as described in Table 5.
Development of formulations  
and drug-loading capacity
The aim of this formulation study was to develop a parenteral 
lipid LNS system with a low toxicity and a high anticancer-
drug loading capacity and to offer an appealing alternative 
to the intravenous administration of CHL and other drugs 
with poor stability. The LNS system is based on the rational 
selection of individual components and composition ratios 
by using a complex formulation composition that presents a 
less toxic and more biocompatible formulation strategy and 
leads to small droplet sizes that are suitable for sterilization 
by filtration.
Since 1984, MCT/LCT emulsions have been in clini-
cal use, and they are more rapidly available to tissues than 
LCT emulsions and show beneficial effects on the immune 
system,18 such as allowing the drug to interact with water-
soluble proteins (eg, lipases) for more efficient in vivo 
hydrolysis and reducing the toxicity associated with pure 
LCT-based lipid emulsions.19 So, the oil composition of the 
lipid nanospheres, was investigated for the production of 
different LNS formulations. Table 3 shows three different International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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types of LNS formulations with different particle sizes, which 
could promote the incorporation of the lipophilic drug and 
subsequently decrease the injected volume. The formulations 
with MCT or LCT/MCT had smaller mean particle sizes, 
and specifically, the MCT/LCT formulations resulted in the 
smallest mean particle sizes. These results indicate that differ-
ent oil components might lead to formulations with different 
structures and might further influence the interfacial tension 
and viscosity of the LNS system.
Additionally, 2% (w/v) E80 was selected to avoid LNS 
gelatinization. In order to formulate a nano-sized lipid drug 
carrier that would be acceptable for   intravenous administration 
and would achieve a maximum drug-stabilization effect by 
forming a high-energy barrier at the oil–water interface,20 
additional stabilizing surfactant combinations (Lutrol F 68 and 
Tween 80) were used. The percentage of the total surfactant 
combination amount was up to 6% (w/v), which was neces-
sary to cover the total interfacial oil–water surface during the 
LNS preparations. The three surfactants were used to reduce 
the toxicity of each surfactant. Table 4 shows the average 
particle size with the change of surfactant combination. 
Therefore, different LNS were obtained and compared by 
selecting system surfactant combinations of Tween 80, Lutrol 
F 68 and phospholipids with different hydrophile–lipophile 
balance (HLB) values, which were about 15, 29 and 8 (10), 
respectively. Furthermore, the use of MCT and Tween 80 in 
this complex LNS   formulation facilitates particle size reduc-
tion and filter-sterilization through a 0.22-µm membrane. The 
optimized intravenous LNS formulation (MCT: 10 mg⋅mL−1, 
LCT: 10 mg⋅mL−1, monostearin 40: mg⋅mL−1, E80: 
20 mg⋅mL−1,Tween 80:30 mg⋅mL−1, Lutrol F 68:10 mg⋅mL−1) 
showed a very narrow distribution range from 90–150 nm in 
diameter with a polydispersity index of 0.017.
The results of three different batches of the formulation 
are presented individually in Table 5, in which the drug 
incorporation and loading capacity can be compared for the 
amount of added drug.
From the results, we can conclude that acetic acid was 
effective in minimizing drug hydrolysis and was essential 
for a high drug-encapsulation efficiency. CHL was also 
easily dissolved in the oil phase by adding acetic acid to 
the oil phase. However, when drug loading increased from 
0.7 to 1.5 mg⋅mL−1, a decreased drug-entrapment efficiency 
trend was observed; thus, 0.7 mg⋅mL−1 was deemed to be an 
appropriate drug loading content.
Freeze-drying
The reconstitution of lyophilized LNS is one of the most 
important factors in the whole process of the preparation 
and practical application of nanospheres. For long-term 
storage considerations, aqueous suspensions of LNS are 
essential for lyophilization and must be reconstituted into 
physiological suspensions as the original aqueous suspen-
sions before use.
The protective effect of cryoprotectants (15%, w/v  )  on 
the physical properties and redispersion of lyophilized LNS 
was investigated. Table 6 shows that these formulations had 
relatively good redispersion rates. The optimized combina-
tion of cryoprotectants was 7.5% sucrose and 7.5% mannitol. 
Sucrose can inhibit mannitol crystallization of the LNS to 
achieve elegant lyophilized products.21 Such excipients can 
protect the lipid matrix more efficiently during the freeze-
drying process. The particle size and range of distribution 
Table 3 effect of different lipophilic mixtures on lipid nanospheres 
droplet  size  and  entrapment  efficiency  (EE%);  aqueous  phase 
composed of surfactants 1 (e80: 20 mg⋅mL−1, Tween 80: 30 mg⋅mL−1, 
Lutrol F 68: 10 mg⋅mL−1), and 0.7 mg drugs added per mL of lipid 
nanospheres
Sample number DA 
(mg⋅mL-1)
MDS EE%
Lipophilic mixture 1 0.48 130 ± 0.018 80.32 ± 0.01
Lipophilic mixture 2 0.43 127 ± 0.017 75.28 ± 0.01
Lipophilic mixture 3 0.52 129 ± 0.018 68.11 ± 0.01
Abbrevations: DA, drug load; MDS, mean droplet size.
Table 4 effect of composition of surfactants on lipid nanospheres 
droplet  size  and  entrapment  efficiency  (EE%);  lipid  mixtures 
composed  of  lipophilic  mixture  2  (McT:  10  mg⋅mL−1,  LcT: 
10 mg⋅mL−1, monostearin 40: mg⋅mL−1), 0.7 mg drugs added for 
per mL of lipid nanospheres
Sample 
number
DA 
(mg⋅mL-1)
MDS Entrapment 
efficiency (%)
Surfactant 1 0.48 127 ± 0.017 61.22 ± 0.004
Surfactant 2 0.47 133 ± 0.018 55.33 ± 0.015
Surfactant 3 0.48 141 ± 0.019 52.66 ± 0.100
Abbreviations: McT, medium-chain triglycerides; MDS, mean droplet size.
Table 5 Drug loading amount and entrapment efficiency (EE%) of 
the optimized lipid nanospheres (formulation composed of lipophilic 
mixture  2:  McT:  10  mg⋅mL−1,  LcT:  10  mg⋅mL−1,  monostearin 
40: mg⋅mL−1, and surfactant mixture 1: e80: 20 mg⋅mL−1, Tween 80: 
30 mg⋅mL−1, Lutrol F 68:10 mg⋅mL−1)
Sample number DA (mg⋅mL-1) EE%
1 0.72 99.28
2 1.07 99.83
3 1.43 98.57
Abbreviations: DA, drug load; LcT, long-chain triglycerides; McT, medium-chain 
triglycerides.International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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of the lyophilized LNS after reconstitution are shown in 
Figure 2. Three   distribution peaks are shown, indicating that 
a new distinct population of particles had formed. Freeze-
drying is a complex drying process during the conversion of 
LNS solutions into solid materials, and it leads to particle 
growth and aggregation. The heterogeneous distribution of 
freeze-dried LNS mainly depended on the composition of 
this distinct formulation, such as the effects of monostearin, 
Tween 80 and phospholipid. The presence of Tween 80 led 
to a large size-distribution during the freeze-drying process. 
This finding was also reported by Lim and Kim,22 where lyo-
philized SLN with 54:46, 100:0 or 0:100 weight ratios of egg 
phosphatidylcholine: Tween 80 for the controlled release of 
all-trans-retinoic acid resulted in mean particle sizes of SLN 
of 329.5, 440.3 and 1459.7 nm, respectively. Zimmermann 
et al23 reported that liposomes form after reconstitution, 
which may explain why LNS size aggregation occurred in 
this present study.
Because the formulation effect by which excipients 
preserve the native structure of LNS during freeze-drying 
is incompletely understood, the optimization of intravenous 
LNS remains a challenge. Therefore, to better understand 
the effect of LNS components on particle size after recon-
stitution, two types of LNS formulations were prepared and 
lyophilized, with a MCT:LCT:monostearin mixture used 
as the oil. One was a PEG-40 formulation in which we 
replaced Tween 80 in optimized LNS with PEG-40; after 
reconstitution, the particle size distribution values of the 
PEG-40 formulation were 87.7 nm (D10), 114 nm (D50) and 
1422 nm (D90), while the particle size distribution values 
of the Tween 80 formulation were 98.4 nm (D10), 129 nm 
(D50) and 231 nm (D90), respectively. The D50 of the 
Tween 80 formulation was slightly increased, but it still had 
a relatively homogeneous particle size distribution. The final 
results showed that the Tween 80 component could improve 
the particle size distribution.
As all the LNS particles were smaller than 3 µm, its   
parenteral use by intravenous injection is acceptable.24 
No droplets should be larger than 5 µm to avoid possible 
embolism in the lung capillaries. We would expect that 
Table 6 effects of cryoprotectants on morphological characteristics of reconstituted lipid nanospheres from freeze-dried suspension 
(cryoprotectant concentration %)
No. Sucrose Trehalose Mannitol Glucose Physical 
propertiesa
Speed of 
redispersionb
1 +++ −
2 15 ++ −
3 15 − −
5 7.5 7.5 + −
6 10 5 + ++
7 7.5 7.5 +++ +
8 5 5 5 +++ +
9 5 5 5 + ++
10 5 10 +++ ++
11 5 10 − +++
Notes: aThe physical properties were graded from excellent to bad (+++ . ++ . + . −); bThe speed of redispersion was graded from fast to slow (+++ . ++ . + . −).
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Figure 2 Mean particle size diameters of formulations after reconstitution with an 
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in clinical use the LNS would be administered through a 
0.45-µm needle-filtrate for safety considerations.
Transmission electron microscopy
TEM was used to investigate the morphology of this 
transparent LNS system to characterize the LNS after 
high- pressure homogenization. The final LNS had 
spherical or ellipsoidal particle shapes Figure 3, with most 
particle diameters ,100 nm; however, the image diameters 
determined by TEM were smaller than those determined 
by LD. Drug crystals were invisible, and separated oil droplets 
were also not visible in the   electron micrographs, indicating 
that the LNS components are not completely separated in 
the LNS dispersion. The different types of morphologies of 
lipid nanospheres could be explained by the formation of 
extra solid lipid nanoparticles and liposomes, hence the term 
LNS. For special formulations, however, this formulation also 
could be called a lipid nanocomplex (LNC).
DSc investigations
The polymorphic modification of the lipid particle matrix is 
one of the most important factors affecting drug incorporation. 
DSC gives information on the melting and recrystallization 
behavior of the lipophilic mixture. After heating, the crystal 
of the LNS lattice breaks down. Typical DSC tests of the 
  nanospheres as well as those of blank nanospheres and raw 
materials are displayed in Figure 4. The corresponding DSC 
data show the melting processes of the bulk matrix, lyophilized 
drug-free LNS and lyophilized drug-loaded LNS powder over 
a wide melting range. Furthermore, the impurities or less-
ordered crystals of LNS that were influenced by the oil mixture 
of LCT and MCT are also reflected by the heating curve.
To compare the maximum melting temperatures of the 
physical mixture material and LNS, the melting peaks of drug 
(60°C), monostearin (55°C) and Lutrol F 68 (52°C) were all 
established. The physical mixture’s peak was 49.17°C, and 
those of drug-free and drug-loaded LNS were 47.07°C and 
47.10°C, respectively. The decrease in the temperature peaks 
of drug-loaded and drug-free LNS according to the physical 
mixture of their components, could be explained by the fact 
that a monostearin polymorph might be formed during the   
Figure  3  A  transmission  electron  microscopy  image  of  2%  phosphotungstic 
acid-stained lipid nanospheres (ph adjusted to 7.4 with 0.1 mol/L−1 NaOh after 
preparation) (×40,000, bar = 200 nm).
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Figure 6 Distribution profiles in various organs after iv administration of lipid nanospheres of chlorambucil (CHL-LNS) and free chlorambucil (CHL) at a dose of 10 mg⋅kg−1 
in mice.
Note: Bars represent standard error of 3 determinations.
previous heating to obtaining the LNS.25 Another possible 
reason for the decrease in the maximum temperature could 
be the small-size effect,26 as explained by the Thomson 
equation.
In vivo studies
A rapid and sensitive RP-HPLC method was developed 
to determine the CHL levels in rat plasma. A new internal 
standard substance was selected as an alternative to praziqu-
antel, which was reported by another research group,14 accord-
ing to the chosen absorption spectrum of CHL at a wavelength 
of 258 nm to achieve a high selectivity against endogenous 
compounds in the chromatograms. Compared with a previ-
ous study,14 the present method is more suitable, had a rela-
tively simple sample preparation process and eliminated the 
potential degradation of CHL. A value of 0.2 µg⋅mL−1 was 
identified as the lower limit of quantification. The calibration 
curve was linear in the range of 0.2–20 µg⋅mL−1. The plasma 
concentration–time curves of CHL in rats after intravenous 
administration of 10 mg⋅kg−1 CHL-LNS or injection are 
shown in Figure 5 The main   pharmacokinetic parameters 
for each formulation were   calculated using Drug and Statis-
tics (DAS 2.1.1; Mathematical Pharmacology Professional 
Committee of China, Shanghai, China), and the data on both International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
Dovepress 
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Table 7 Pharmacokinetic parameters after iv administration of 
chlorambucil (chL) injection and lipid nanospheres (chL-LNS) 
to mice
CHL (± SD; %) CHL-LNS (± SD, %)
t1/2α min 0.985 ± 0.477 16.143 ± 13.935
t1/2β min 17.365 ± 1.983 23.369 ± 4.311
V1 L⋅kg−1 0.018 ± 0.017 0.217 ± 0.175
cL L⋅min−1⋅kg−1 0.011 ± 0.003 0.008 ± 0
AUc (0–t) mg⋅L−1⋅min 1426.87 ± 262.332 2087.778 ± 129.56
AUc (0–∞) mg⋅L−1⋅min 1790.917 ± 368.64 2473.315 ± 107.02
MrT (0–t) min 16.019 ± 1.109 23.733 ± 3.196
Abbreviations: AUc, area under the concentration time curve; cL, clearance;   
V1, steady-state apparent volume of distribution; MrT, mean retention time.
curves fit a two-compartment model, with the parameters 
shown in Table 7. Statistical analysis of concentration–time 
curve (AUC), clearance, and   steady-state apparent volume 
of distribution of CHL after infusion of the LNS indicated 
slight differences from those values obtained after infusion 
of the solution. This could be caused by rapid drug release 
and degradation, when the concentration of the drug in vivo 
compared with that in plasma was reduced rapidly. We believe 
that drugs that degrade rapidly are not appropriate to be used 
as model drugs in the study of drug release characteristic 
of this LNS. Furthermore, to further understand this LNS 
structure and its drug release mechanism, the study of other 
stable lipophilic model drugs is suggested. According to 
Zhigaltsev,7 rapid release of a drug will eliminate the benefits 
of formulation encapsulation, resulting in efficacy similar to 
that of an equivalent dose of free drug. The balance between 
retention and release must be established to maximize thera-
peutic activity.
Tissue levels of CHL are shown in Figure 6. When 
tissue drug concentrations of both CHL and CHL-LNS 
are taken into account, these five organs were exposed to 
higher CHL-LNS drug concentrations than after infusion of 
the solution. This result was due to the redistribution of the 
LNS. It should be noted that drugs within the lipid of the LNS 
contributed to the increased uptake by tissues. In accord with 
the protection against hydrolysis afforded by the LNS, we 
speculate that the special structure of LNS attenuates tissue 
penetration relative to the solution formulation.
In summary, we successfully evaluated a new type of 
lipid nanosphere with a mixture of emulsifiers for intrave-
nous use in a pharmacokinetics study after the intravenous 
administration of 10 mg⋅kg−1 of CHL to healthy rats via tail 
vein injection. In vivo data showed that CHL in LNS was 
rapidly eliminated following intravenous injection. The fol-
lowing three factors should be considered in complex LNS 
formulation development: small particle size, a certain type 
of lipid matrix and an optimized drug solubility (drug/lipid 
ratio). Small particle sizes lead to large surface areas on 
the nanospheres, and some drugs are adsorbed on to the 
surface of the lipid matrix; structurally different complex 
lipid matrices are also incorporated into each other. These in 
vitro formulation factors allow the interaction of LNS with 
lipases for more efficient hydrolysis and lead to rapid in vivo 
drug release. The drug/lipid ratio is the main formulation 
parameter in LNS formulation development responsible 
for enhancing the drug concentration distribution in the in 
vivo tissues.
Conclusions
The LNS were designed for parenteral use by incorporating 
the anticancer drug CHL in to the lipophilic mixtures. This 
process may provide a means for optimizing the composition 
and production parameters of LNS. The inclusion of monos-
tearin in the LNS formation led to different drug-loading 
properties. The characteristics of this formulation were evalu-
ated, and the results indicated that the new LNS are a good 
intravenous drug carrier after reconstitution. The LNS have 
advantages for intravenous use, such as a small particle size, 
a low toxicity and good reconstituting   dispersion qualities 
after reconstitution. Although this formulation strategy led 
to rapid drug release, it offers the potential for the develop-
ment of further methods of drug delivery for a wide variety 
of anticancer drugs.
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